Previous studies have shown that the CD8 TRM-IFNG signature was a strong predictor for prolonged OS in patients with melanoma (41) and was enriched in the early disease stage of clear cell renal cell carcinoma (12). This evidence concerns the gene IFNG and clear cell renal carcinoma.